ArticleInfectious diseases & clinical microbiology2026
Novel Antibiotics and Emerging Resistance:
Article in Infectious diseases & clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The global spread of antibiotic resistance, particularly in carbapenem-resistant Gram-negative bacteria, has become a major public health concern. Recently developed antibiotics-ceftazidime-avibactam (CAZ-AVI), ceftolozane-tazobactam (TOL-TAZ), meropenem-vaborbactam (MER-VAB), eravacycline (ERV), and delafloxacin (DLX)-represent promising therapeutic alternatives. This study aimed to assess resistance patterns to these novel agents among Materials and Methods: Between January 2023 and December 2024, isolates obtained from ICU cultures at Uşak Training and Research Hospital were analyzed. Species identification was performed using the VITEK® 2 and VITEK® MS systems (bioMérieux, Marcy-l'Étoile, France). Antimicrobial susceptibility testing was conducted with the VITEK® 2 AST XN21 card (bioMérieux, Marcy-l'Étoile, France), while colistin (COL) susceptibility was determined by broth microdilution. Results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and statistical analysis was performed using Pearson's chi-square test ( Results: A total of 1525 clinical samples yielded 850 Conclusion: Although novel β-lactam/β-lactamase inhibitor combinations expand therapeutic options against multidrug-resistant Gram-negative infections, high resistance rates-particularly among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.